2021
Combined ASBT Inhibitor and FGF15 Treatment Improves Therapeutic Efficacy in Experimental Nonalcoholic Steatohepatitis
Matye D, Wang H, Luo W, Sharp R, Chen C, Gu L, Jones K, Ding W, Friedman J, Li T. Combined ASBT Inhibitor and FGF15 Treatment Improves Therapeutic Efficacy in Experimental Nonalcoholic Steatohepatitis. Cellular And Molecular Gastroenterology And Hepatology 2021, 12: 1001-1019. PMID: 33965587, PMCID: PMC8346663, DOI: 10.1016/j.jcmgh.2021.04.013.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBile Acids and SaltsCholesterolCombined Modality TherapyDependovirusDisease Models, AnimalFibroblast Growth FactorsFructoseGene Expression ProfilingGene Expression RegulationGenetic TherapyGenetic VectorsMaleMethylaminesMiceNon-alcoholic Fatty Liver DiseaseThiazepinesTreatment OutcomeConceptsNonalcoholic steatohepatitisBile acid synthesisTherapeutic efficacyFGF19 analogueASBT inhibitorTreatment-associated adverse eventsFecal bile acid excretionASBT inhibitionDiet-induced nonalcoholic steatohepatitisHepatic bile acid synthesisWeight lossBile acid excretionGrowth factor 15Experimental nonalcoholic steatohepatitisDiet-fed miceFurther clinical studiesNew treatment strategiesIntestinal lipid absorptionAdverse eventsAdipose inflammationMetabolic improvementTreatment attenuatesLipid malabsorptionClinical findingsTreatment strategies
2020
Gastrointestinal Injury Related to Antiangiogenesis Cancer Therapy
Tang T, Abu-Sbeih H, Ma W, Lu Y, Luo W, Foo W, Richards D, Halperin D, Ge P, Wang Y. Gastrointestinal Injury Related to Antiangiogenesis Cancer Therapy. Clinical Colorectal Cancer 2020, 19: e117-e123. PMID: 32284253, DOI: 10.1016/j.clcc.2020.03.002.Peer-Reviewed Original ResearchConceptsAbnormal endoscopic findingsAntiangiogenesis cancer therapyIntensive care unitAntiangiogenesis therapyACD symptomsAntimotility agentsEndoscopic findingsColonic perforationCare unitTertiary care cancer centerActive histologic inflammationRare adverse eventsCancer therapyEnterocolitis symptomsHistologic inflammationNonulcerative inflammationUnderlying malignancyGastrointestinal injuryGastrointestinal toxicityMucosal ulcerationUnderwent endoscopyAdverse eventsMedian durationMost patientsEndoscopic evaluation
2019
Gastrointestinal Adverse Events Observed After Chimeric Antigen Receptor T-Cell Therapy
Abu-Sbeih H, Tang T, Ali F, Luo W, Neelapu S, Westin J, Okhuysen P, Foo W, Curry J, Richards D, Ge P, Wang Y. Gastrointestinal Adverse Events Observed After Chimeric Antigen Receptor T-Cell Therapy. American Journal Of Clinical Oncology 2019, 42: 789-796. PMID: 31478934, DOI: 10.1097/coc.0000000000000596.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge DistributionAntineoplastic Combined Chemotherapy ProtocolsAsparaginaseBiopsy, NeedleCohort StudiesCytarabineDaunorubicinFemaleGastric MucosaGastritisGastrointestinal DiseasesHematologic NeoplasmsHumansImmunohistochemistryImmunotherapy, AdoptiveIncidenceMaleMiddle AgedPrognosisReceptors, Chimeric AntigenRetrospective StudiesRisk AssessmentSeverity of Illness IndexSex DistributionThioguanineConceptsChimeric antigen receptor T-cell therapyCytokine release syndromeGastrointestinal adverse eventsGI AEsT-cell therapyRefractory colitisEncephalopathy syndromeRelease syndromeAdverse eventsHematologic malignanciesDiffuse large B-cell lymphomaLarge B-cell lymphomaGastrointestinal tract inflammationGrade 1 diarrheaOnly symptomatic treatmentStandard of careCertain hematologic malignanciesB-cell lymphomaCART infusionAbdominal distensionAbdominal painBloody stoolGastrointestinal symptomsMedian durationExperienced diarrheaUpper gastrointestinal symptoms and associated endoscopic and histological features in patients receiving immune checkpoint inhibitors
Tang T, Abu-Sbeih H, Luo W, Lum P, Qiao W, Bresalier R, Richards D, Wang Y. Upper gastrointestinal symptoms and associated endoscopic and histological features in patients receiving immune checkpoint inhibitors. Scandinavian Journal Of Gastroenterology 2019, 54: 538-545. PMID: 31079556, DOI: 10.1080/00365521.2019.1594356.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsUpper GI symptomsRisk factorsGI symptomsCheckpoint inhibitorsGI inflammationAnti-PD-1/L1Non-steroidal anti-inflammatory drugsUpper GI injuryUpper GI toxicityGastrointestinal adverse eventsUpper gastrointestinal symptomsProton pump inhibitorsLower GI tractAnti-inflammatory drugsRate of ulcerationGI injuryICI initiationDuodenal involvementEndoscopic evidenceGastrointestinal symptomsGI toxicityImmunosuppressive therapyAdverse eventsGastric involvementVedolizumab Achieved Clinical and Histologic Remission in a Patient with Lung Cancer Who Had a Steroid-Refractory Upper Gastrointestinal Injury Due to Nivolumab Treatment
Tran C, Abu-Sbeih H, Luo W, Lu Y, Wang Y. Vedolizumab Achieved Clinical and Histologic Remission in a Patient with Lung Cancer Who Had a Steroid-Refractory Upper Gastrointestinal Injury Due to Nivolumab Treatment. Journal Of Immunotherapy And Precision Oncology 2019, 2: 40-45. DOI: 10.4103/jipo.jipo_18_18.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsLung cancerSteroid courseAdverse eventsAbstract Immune checkpoint inhibitorsUpper GI adverse eventsSignificant anti-tumor effectGI adverse eventsProgressive lung cancerUpper gastrointestinal injuryUpper GI toxicityAnti-tumor effectsNovel therapeutic classResolution of inflammationGI-irAEsHistologic remissionHistological remissionNivolumab treatmentVedolizumab treatmentCheckpoint inhibitorsClinical remissionGastrointestinal injuryGI toxicityPrednisone taperSevere nausea